Teligent's Post-Sale Drug Recall Puts Its Ch. 11 Plan In Doubt
By Leslie A. Pappas · June 17, 2022, 7:25 PM EDT
The Chapter 11 plan for the generic-drug maker once known as Teligent Inc. was thrown into doubt Friday after a bankruptcy court ruled that the company owes a refund for drugs it sold...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login